Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Pirtobrutinib on QTc Interval in Healthy Subjects
NCT06215521Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pirtobrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction at 24 hours. Started Dec 2020; status: completed.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06215521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215521.